 Shelley Miyamoto
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 39 | 2025 | 747 | 5.270 |
Why?
| | Heart Defects, Congenital | 15 | 2024 | 834 | 2.600 |
Why?
| | Heart Failure | 19 | 2025 | 2234 | 2.580 |
Why?
| | Cardiomyopathy, Dilated | 14 | 2025 | 383 | 2.480 |
Why?
| | Heart Ventricles | 15 | 2022 | 792 | 2.380 |
Why?
| | Heart-Lung Transplantation | 2 | 2025 | 14 | 1.940 |
Why?
| | MicroRNAs | 9 | 2025 | 699 | 1.910 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 25 | 1.600 |
Why?
| | Cardiomyopathies | 7 | 2023 | 350 | 1.550 |
Why?
| | Disease Management | 4 | 2025 | 627 | 1.550 |
Why?
| | Lung Transplantation | 2 | 2025 | 308 | 1.540 |
Why?
| | Myocardium | 8 | 2021 | 1002 | 1.450 |
Why?
| | Societies, Medical | 2 | 2025 | 822 | 1.420 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 121 | 1.350 |
Why?
| | Myocytes, Cardiac | 8 | 2025 | 528 | 1.330 |
Why?
| | Milrinone | 2 | 2021 | 29 | 1.190 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 262 | 1.160 |
Why?
| | Child | 65 | 2025 | 21999 | 1.040 |
Why?
| | Graft Rejection | 9 | 2025 | 620 | 1.020 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 142 | 0.960 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 283 | 0.960 |
Why?
| | Heart Diseases | 5 | 2023 | 359 | 0.930 |
Why?
| | Ventricular Function, Left | 6 | 2024 | 540 | 0.890 |
Why?
| | Graft Survival | 8 | 2025 | 534 | 0.750 |
Why?
| | Infant | 33 | 2025 | 9451 | 0.710 |
Why?
| | Child, Preschool | 40 | 2025 | 11080 | 0.700 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 127 | 0.640 |
Why?
| | Down-Regulation | 4 | 2025 | 658 | 0.630 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 93 | 0.630 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 14 | 0.620 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1577 | 0.620 |
Why?
| | Fever | 1 | 2020 | 308 | 0.600 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.600 |
Why?
| | Humans | 87 | 2025 | 137294 | 0.550 |
Why?
| | Steroids | 2 | 2015 | 168 | 0.540 |
Why?
| | Hemodynamics | 6 | 2015 | 1110 | 0.520 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 145 | 0.520 |
Why?
| | Female | 64 | 2025 | 73052 | 0.490 |
Why?
| | Male | 59 | 2025 | 67560 | 0.490 |
Why?
| | Fontan Procedure | 4 | 2023 | 180 | 0.490 |
Why?
| | Histone Deacetylases | 1 | 2017 | 215 | 0.480 |
Why?
| | Case-Control Studies | 9 | 2025 | 3546 | 0.440 |
Why?
| | Echocardiography | 6 | 2021 | 659 | 0.430 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 890 | 0.410 |
Why?
| | Biomarkers | 9 | 2021 | 4164 | 0.400 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 549 | 0.390 |
Why?
| | Adolescent | 37 | 2025 | 21499 | 0.390 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 45 | 0.390 |
Why?
| | Waiting Lists | 2 | 2013 | 262 | 0.380 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 2113 | 0.370 |
Why?
| | Animals, Newborn | 5 | 2021 | 844 | 0.370 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 218 | 0.370 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 46 | 0.360 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 25 | 0.360 |
Why?
| | Recovery of Function | 2 | 2015 | 657 | 0.360 |
Why?
| | Dexmedetomidine | 3 | 2017 | 44 | 0.350 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2608 | 0.350 |
Why?
| | Age Factors | 10 | 2024 | 3297 | 0.340 |
Why?
| | Connexin 43 | 2 | 2025 | 31 | 0.330 |
Why?
| | Phenotype | 4 | 2023 | 3202 | 0.320 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 30 | 0.310 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 292 | 0.310 |
Why?
| | Cardiolipins | 3 | 2021 | 85 | 0.310 |
Why?
| | Reoviridae Infections | 1 | 2009 | 54 | 0.300 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2486 | 0.290 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 13 | 0.290 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 66 | 0.290 |
Why?
| | Retrospective Studies | 23 | 2024 | 15639 | 0.290 |
Why?
| | Everolimus | 2 | 2025 | 91 | 0.290 |
Why?
| | Prospective Studies | 11 | 2021 | 7595 | 0.290 |
Why?
| | American Heart Association | 3 | 2024 | 306 | 0.280 |
Why?
| | Myocarditis | 1 | 2009 | 101 | 0.280 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 528 | 0.280 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 612 | 0.270 |
Why?
| | Signal Transduction | 3 | 2017 | 5078 | 0.270 |
Why?
| | Coronary Artery Disease | 4 | 2024 | 703 | 0.270 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 346 | 0.270 |
Why?
| | Tacrolimus | 2 | 2025 | 199 | 0.270 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 43 | 0.260 |
Why?
| | Kidney Transplantation | 2 | 2023 | 701 | 0.260 |
Why?
| | Phosphorylation | 4 | 2021 | 1759 | 0.260 |
Why?
| | Databases, Factual | 5 | 2016 | 1355 | 0.250 |
Why?
| | Calcium | 3 | 2021 | 1198 | 0.250 |
Why?
| | Treatment Outcome | 15 | 2024 | 10800 | 0.240 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 87 | 0.230 |
Why?
| | Infant, Newborn | 10 | 2021 | 6054 | 0.230 |
Why?
| | Coronary Vessels | 2 | 2017 | 246 | 0.230 |
Why?
| | Fibrosis | 2 | 2017 | 552 | 0.220 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 552 | 0.220 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 745 | 0.210 |
Why?
| | Allografts | 1 | 2024 | 146 | 0.210 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 10 | 0.210 |
Why?
| | Heart | 3 | 2022 | 657 | 0.200 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1084 | 0.200 |
Why?
| | Sarcomeres | 1 | 2023 | 95 | 0.200 |
Why?
| | Cyclic AMP | 2 | 2014 | 234 | 0.190 |
Why?
| | Fibroma | 1 | 2022 | 22 | 0.190 |
Why?
| | Data Accuracy | 1 | 2022 | 65 | 0.190 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2024 | 389 | 0.190 |
Why?
| | Heart Neoplasms | 1 | 2022 | 52 | 0.190 |
Why?
| | Barth Syndrome | 1 | 2021 | 8 | 0.190 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 41 | 0.180 |
Why?
| | Focal Adhesions | 1 | 2021 | 44 | 0.180 |
Why?
| | Transcriptome | 2 | 2021 | 972 | 0.180 |
Why?
| | Longevity | 1 | 2022 | 165 | 0.180 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 424 | 0.180 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 26 | 0.180 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 210 | 0.170 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 12 | 0.170 |
Why?
| | Probenecid | 1 | 2020 | 8 | 0.170 |
Why?
| | Cytokines | 1 | 2009 | 2090 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2019 | 4197 | 0.170 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 66 | 0.170 |
Why?
| | Amniotic Fluid | 1 | 2021 | 96 | 0.170 |
Why?
| | Heart Rate | 3 | 2023 | 823 | 0.170 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2032 | 0.170 |
Why?
| | Serum | 2 | 2018 | 59 | 0.170 |
Why?
| | Young Adult | 13 | 2024 | 13163 | 0.170 |
Why?
| | Isoproterenol | 2 | 2018 | 113 | 0.170 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 125 | 0.170 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1904 | 0.160 |
Why?
| | Apoptosis | 1 | 2009 | 2554 | 0.160 |
Why?
| | ROC Curve | 3 | 2017 | 548 | 0.160 |
Why?
| | Time Factors | 7 | 2024 | 6818 | 0.160 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 132 | 0.160 |
Why?
| | Risk Factors | 11 | 2024 | 10368 | 0.160 |
Why?
| | Atrial Function, Right | 1 | 2019 | 12 | 0.160 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 38 | 0.150 |
Why?
| | Troponin I | 1 | 2019 | 84 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 89 | 0.150 |
Why?
| | Fatty Acids | 1 | 2021 | 444 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 37 | 0.150 |
Why?
| | Tissue Donors | 3 | 2016 | 417 | 0.150 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 100 | 0.140 |
Why?
| | Heart Atria | 1 | 2019 | 136 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 22 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 566 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 309 | 0.140 |
Why?
| | Rats | 5 | 2025 | 5639 | 0.140 |
Why?
| | Animals | 11 | 2025 | 36862 | 0.140 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 21 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 527 | 0.140 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 18 | 0.140 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.130 |
Why?
| | Survival Analysis | 4 | 2021 | 1321 | 0.130 |
Why?
| | Patient Transfer | 1 | 2019 | 168 | 0.130 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 18 | 0.130 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 185 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 892 | 0.130 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.130 |
Why?
| | Galectin 3 | 1 | 2016 | 21 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 786 | 0.130 |
Why?
| | Vectorcardiography | 1 | 2016 | 5 | 0.130 |
Why?
| | Electrocardiography | 3 | 2015 | 630 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 344 | 0.130 |
Why?
| | Adult | 13 | 2024 | 37724 | 0.130 |
Why?
| | Cytomegalovirus Infections | 2 | 2025 | 191 | 0.130 |
Why?
| | Isoenzymes | 1 | 2017 | 304 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 375 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 181 | 0.130 |
Why?
| | Transition to Adult Care | 1 | 2017 | 81 | 0.130 |
Why?
| | Research Design | 1 | 2022 | 1128 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 284 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 213 | 0.120 |
Why?
| | Vascular Resistance | 1 | 2017 | 372 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 275 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 181 | 0.120 |
Why?
| | Vasoconstriction | 1 | 2017 | 202 | 0.120 |
Why?
| | Exosomes | 1 | 2017 | 103 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 313 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 333 | 0.120 |
Why?
| | Mutation | 3 | 2023 | 3956 | 0.120 |
Why?
| | Up-Regulation | 1 | 2018 | 844 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 544 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 84 | 0.120 |
Why?
| | Follow-Up Studies | 7 | 2024 | 5125 | 0.120 |
Why?
| | Ketamine | 1 | 2015 | 93 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.110 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 89 | 0.110 |
Why?
| | Exercise Test | 3 | 2023 | 625 | 0.110 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 175 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 310 | 0.110 |
Why?
| | Myocardial Contraction | 3 | 2024 | 340 | 0.110 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 30 | 0.110 |
Why?
| | Stroke Volume | 2 | 2016 | 619 | 0.110 |
Why?
| | Coronary Angiography | 1 | 2016 | 312 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 117 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1774 | 0.110 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 11 | 0.110 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 199 | 0.110 |
Why?
| | Growth Disorders | 1 | 2014 | 86 | 0.110 |
Why?
| | Anthracyclines | 1 | 2013 | 48 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 577 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 290 | 0.100 |
Why?
| | Prognosis | 4 | 2015 | 4026 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2016 | 244 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2016 | 247 | 0.100 |
Why?
| | Fetal Heart | 1 | 2013 | 55 | 0.100 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 191 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 49 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2016 | 964 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 762 | 0.100 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 314 | 0.100 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 101 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 339 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 182 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 188 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1063 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 236 | 0.090 |
Why?
| | Postoperative Complications | 5 | 2025 | 2658 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.090 |
Why?
| | Altitude | 2 | 2021 | 485 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 67 | 0.080 |
Why?
| | Lymphoproliferative Disorders | 1 | 2010 | 55 | 0.080 |
Why?
| | Incidence | 2 | 2015 | 2808 | 0.080 |
Why?
| | United States | 8 | 2024 | 14742 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 226 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 272 | 0.080 |
Why?
| | Mycoses | 1 | 2010 | 79 | 0.080 |
Why?
| | Patient Selection | 1 | 2014 | 692 | 0.080 |
Why?
| | Air Ambulances | 1 | 2010 | 32 | 0.080 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 415 | 0.080 |
Why?
| | RNA | 1 | 2016 | 924 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 170 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 84 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1456 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2023 | 696 | 0.080 |
Why?
| | Colorado | 6 | 2017 | 4527 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1327 | 0.080 |
Why?
| | Travel | 1 | 2010 | 129 | 0.080 |
Why?
| | Cohort Studies | 6 | 2015 | 5726 | 0.080 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 18 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 530 | 0.070 |
Why?
| | Registries | 2 | 2014 | 2016 | 0.070 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 93 | 0.070 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 6 | 0.070 |
Why?
| | Cell Line | 2 | 2025 | 2841 | 0.070 |
Why?
| | Reoperation | 3 | 2021 | 583 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2021 | 2839 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 91 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 1069 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 593 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 343 | 0.060 |
Why?
| | Pregnancy | 2 | 2021 | 6743 | 0.060 |
Why?
| | Stents | 1 | 2009 | 529 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2025 | 145 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2850 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1134 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2025 | 403 | 0.050 |
Why?
| | Echocardiography, Doppler | 1 | 2024 | 109 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 315 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1061 | 0.050 |
Why?
| | Risk | 2 | 2019 | 908 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 1700 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1226 | 0.050 |
Why?
| | Palliative Care | 1 | 2009 | 747 | 0.050 |
Why?
| | Middle Aged | 4 | 2016 | 33310 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 767 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2836 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 17 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 55 | 0.050 |
Why?
| | Acyltransferases | 1 | 2021 | 56 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 8 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 33 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 96 | 0.040 |
Why?
| | Fetoscopy | 1 | 2021 | 30 | 0.040 |
Why?
| | Genotype | 2 | 2017 | 1923 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2023 | 279 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1946 | 0.040 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 126 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 808 | 0.040 |
Why?
| | Gene Expression | 2 | 2017 | 1501 | 0.040 |
Why?
| | Drainage | 1 | 2021 | 171 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 40 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1521 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 497 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1059 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2071 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 51 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 284 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 60 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 437 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 3439 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 731 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2195 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2836 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 354 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 200 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 455 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2661 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 158 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1788 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 73 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 812 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 114 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 91 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2025 | 1987 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2017 | 72 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 91 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 100 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 345 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 619 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 84 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 92 | 0.030 |
Why?
| | Brain Death | 1 | 2016 | 46 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 182 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 94 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1467 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 177 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 150 | 0.030 |
Why?
| | Systole | 1 | 2016 | 191 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4284 | 0.030 |
Why?
| | Italy | 1 | 2015 | 109 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 123 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 271 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 164 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 949 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 769 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 166 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 947 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 495 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 818 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 221 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 394 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 125 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 579 | 0.030 |
Why?
| | Exons | 1 | 2015 | 351 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 846 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 85 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 251 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1318 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 206 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1067 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1623 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 891 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 826 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 130 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2014 | 178 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 851 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2012 | 61 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 256 | 0.020 |
Why?
| | Mice | 3 | 2015 | 17774 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1484 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 308 | 0.020 |
Why?
| | Exercise | 1 | 2023 | 2045 | 0.020 |
Why?
| | Nutritional Status | 1 | 2014 | 344 | 0.020 |
Why?
| | Pediatrics | 1 | 2019 | 1113 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1260 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 269 | 0.020 |
Why?
| | France | 1 | 2010 | 33 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 331 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 63 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 985 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 316 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 533 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 165 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 287 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 99 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 155 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1268 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1970 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 5 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 8 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2052 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 23 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 138 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1127 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 152 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 519 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1269 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 662 | 0.020 |
Why?
| | Probability | 1 | 2008 | 309 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 412 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3283 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 305 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 430 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1237 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5769 | 0.010 |
Why?
| | Aged | 2 | 2014 | 23851 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1218 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1998 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|